cell genomics News
-
Feldan congratulates scge program for nature article
Congratulations to the team at NIH Common Fund’s Somatic Cell Genome Editing (SCGE) program for publishing their work in the journal Nature. Feldan is honoured to be part of this initiative alongside its long-standing collaborator, Dr. Paul McCray of the University of Iowa. https://www.nature.com/articles/s41586-021-03191-1 About the collaboration between Dr. McCray and Feldan ...
-
Immunai Raises $215 Million to Accelerate Development of Its Immune-First Drug Actuary Platform
Immunai, a New York-based biotech company, today announced a $215M Series B, increasing the company’s total funding to date to $295M. The new capital will be used to expand Immunai’s “drug actuary” platform for target validation and evaluation. “We have made great progress towards our core mission of understanding the immune system, which we believe is essential to ...
By Immunai
-
Stem Pharm welcomes their newest Advisor, Dr. Edsel Abud
Dr. Edsel Abud has joined Stem Pharm’s talented team of Advisors. While attending University of California Irvine for his MD and PhD as part of the NIH's Medical Scientist Training Program (MSTP), Dr. Abud notably developed one of the first methods to generate human microglia from stem cells, showing their functional genomics and how they play a role in health and disease. Dr. Abud was also ...
-
Immunai Recognized by Fast Company’s 2021 World Changing Ideas Awards
Immunai, a New York and Tel Aviv-based biotech company, today announced that it has been recognized as part of Fast Company’s World Changing Ideas Awards. The awards honor the businesses, policies, projects, and concepts that are actively engaged and deeply committed to pursuing innovation when it comes to solving health and climate crises, social injustice, or economic inequality. Immunai ...
By Immunai
-
Immunai Using Acquisition, Funding to Shift Into Functional Work
With a recently closed $60 million funding round, the acquisition of software company Dropprint Genomics, and additions to its leadership team, immune profiling firm Immunai is looking to expand its functional genomics capabilities to more directly inform immune therapy development and application. Since launching in 2018, the New York City-based company has focused its efforts on multiomic ...
By Immunai
-
NIH Grantees Win 2015 Nobel Prize in Chemistry
The 2015 Nobel Prize in chemistry has been awarded to National Institutes of Health grantees Paul Modrich, Ph.D., of the Howard Hughes Medical Institute and the Duke University School of Medicine, Durham, N.C.; and Aziz Sancar, M.D., Ph.D., of the University of North Carolina, Chapel Hill, N.C., for having mapped, at a molecular level, how cells repair damaged DNA and safeguard the genetic ...
-
Immunai Acquires Dropprint Genomics and Strengthens Leadership Team with Experts in Immunology to Expand Target Discovery Capabilities
Immunai, a New York and Tel Aviv-based biotech company, announced its acquisition of Dropprint Genomics, a San Francisco-based single-cell genomics software company. Immunai is also expanding its executive leadership team and scientific advisory board with experts in immunology, single-cell technologies and machine learning. Both the acquisition and new hires will advance the company’s work ...
By Immunai
-
CD Genomics RNA-Solutions Platform Announces the Launch of Nanopore Direct RNA Sequencing
The RNA Solutions platform offers services to revolutionize RNA study, targeting both coding and non-coding RNAs of different physiological functions. Scientists at CD Genomics are ready to help detect various types of RNA via meticulous and integrative approaches. The company has recently launched the Nanopore direct RNA sequencing service for identifying new genes, transcripts, and alternative ...
By CD Genomics
-
Immunai Raises $60M to Reprogram Immunity
Immunai, a New York and Tel Aviv based biotech company, announced today $60M in funding, increasing the company’s total funding-to-date to over $80M. Immunai integrates multi-omic single-cell analytics and machine learning to identify novel immunological insights that lead to the discovery and development of more effective and targeted immunotherapies. The Series A round was led by ...
By Immunai
-
Berkeley Lights to Participate in the 18th Annual PEGS Boston Conference & Expo
Company’s latest data to be presented on “Rapid High-Throughput Workflow for TCR Discovery on Solid Tumors with Functional Verification” EMERYVILLE, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced its participation at the 18th Annual PEGS Boston Conference, a protein engineering and cell therapy ...
-
TreeFrog Therapeutics launches a $100,000 research grant in regenerative medicine
TreeFrog Therapeutics, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced the launch of The Stem Cell SpaceShot Grant, a $100,000 research funding in the field of stem cell biology and regenerative medicine. The Stem Cell Spaceshot Grant is open to PhD-level scientists and PhD ...
-
NEOVII Partners with Tel Aviv University to Develop Novel COVID-19 Vaccine
Ramot, Tel Aviv University’s technology transfer company, and Neovii, a Swiss-based biopharmaceutical company and a member of Israel-based Neopharm Group, announced today that they have signed a research and license agreement to develop a novel and potentially life-saving COVID-19 vaccine. Neovii will work in close collaboration with a team of scientists led by Prof. Jonathan Gershoni of ...
-
Caribou Biosciences to Participate in Citi’s 16th Annual BioPharma Virtual Conference
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, will participate in a panel discussion entitled “Autologous, Allogeneic CAR-T, CAR-NK & More - Exploring the State of Play in Cell Therapy” on Thursday, September 9, ...
-
CD BioGlyco Announced Service for Analysis of Glycolytic Enzymes in Cancer Cells
CD BioGlyco, a biotechnology company that provides multi-omics analysis of cancer cell glycolysis including genomics, proteomics, metabolomics and metabolic fluxomics, now offers analysis of glycolytic enzymes in cancer cells, enabling thorough understanding of cancer cell glycolysis pathways. The capacity of cancer cells for aerobic glycolysis is 20–30 times greater than that of normal ...
By CD BioGlyco.
-
Immunai acquires single-cell data developer Dropprint Genomics to build out its immune system atlas
Shortly after raising $60 million to fuel its artificial intelligence work, aimed at digitally charting the human body’s immune system, Immunai announced it has acquired the single-cell sequencing software startup Dropprint Genomics. Previously backed by Y Combinator, the San Francisco-based Dropprint aims to provide big data and machine learning solutions to help crunch the numbers ...
By Immunai
-
NIH-Supported Researchers Map Epigenome of More Than 100 Tissue and Cell Types
Much like mapping the human genome laid the foundations for understanding the genetic basis of human health, new maps of the human epigenome may further unravel the complex links between DNA and disease. The epigenome is part of the machinery that helps direct how genes are turned off and on in different types of cells. Researchers supported by the National Institutes of Health Common Fund's ...
-
CD Genomics Redefines Genomic Research with Full-Length Transcripts Sequencing (Iso-Seq)
CD Genomics, a leading provider of genomic solutions, has announced a groundbreaking development in genomic research with the introduction of their Full-Length Transcripts Sequencing (Iso-Seq) technology. This innovative advancement promises to revolutionize the field, providing researchers in the life sciences with an unprecedented opportunity to gain comprehensive insights into the complexity ...
By CD Genomics
-
Opentrons` subsidiary Neochromosome and Mekonos announce new partnership to advance cell engineering for personalized medicine
Mekonos, Inc., a biotech platform company building the future of cell therapies on a chip, has announced a new partnership with Neochromosome, Inc., a wholly-owned subsidiary of Opentrons Labworks focused on the creation of genome-scale cell engineering solutions. The new collaboration is focused on developing new capabilities using cutting-edge synthetic biology technologies to produce advanced ...
-
Caribou Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference
Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, will present a corporate update at the 40TH Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 9:45 am ET. A live webcast of the presentation will be accessible ...
-
Agilent Technologies, Cell Line Genetics Collaborate on High-Throughput Cell-Line Characterization Services for Regenerative Medicine, Cancer Researchers
Agilent Technologies Inc. (NYSE: A) today announced a collaboration with Cell Line Genetics, Inc., a leading provider of cell-line characterization and quality assurance services. CLG will develop high-throughput, genomic characterization workflows to confirm and monitor the integrity of cell lines for translational and regenerative medicine research. The workflows will be based upon Agilent's ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you